Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

danaher corp. - DHR

DHR

Close Chg Chg %
233.15 1.85 0.79%

Closed Market

235.00

+1.85 (0.79%)

Volume: 2.54M

Last Updated:

Nov 21, 2024, 3:59 PM EDT

Trade Now

Company Overview: danaher corp. - DHR

DHR Key Data

Open

$233.82

 Day Range

230.40 - 235.18

52 Week Range

215.69 - 281.70

 Market Cap

$168.36B

Shares Outstanding

722.28M

 Public Float

692.91M

Beta

0.86

 Rev. Per Employee

N/A

P/E Ratio

44.46

 EPS

$5.29

Yield

45.05%

 Dividend

$0.27

EX-DIVIDEND DATE

Sep 27, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

3.18M

  

DHR Performance

1 Week
 
 1.97%
 
1 Month
 
 -4.21%
 
3 Months
 
 -12.78%
 
1 Year
 
 6.16%
 
5 Years
 
 85.77%
 

DHR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28
Full Ratings ➔

About danaher corp. - DHR

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

DHR At a Glance

Danaher Corp.
2200 Pennsylvania Avenue North West
Washington, District of Columbia 20037-1701
Phone 1-202-828-0850 Revenue 23.89B
Industry Medical Specialties Net Income 4.76B
Sector Health Technology Employees 63,000
Fiscal Year-end 12 / 2024
View SEC Filings

DHR Valuation

P/E Current 44.462
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 36.245
Price to Sales Ratio 7.196
Price to Book Ratio 3.197
Price to Cash Flow Ratio 23.996
Enterprise Value to EBITDA 24.927
Enterprise Value to Sales 7.768
Total Debt to Enterprise Value 0.105

DHR Efficiency

Revenue/Employee 379,206.349
Income Per Employee 75,619.048
Receivables Turnover 5.152
Total Asset Turnover 0.283

DHR Liquidity

Current Ratio 1.684
Quick Ratio 1.371
Cash Ratio 0.709

DHR Profitability

Gross Margin 58.744
Operating Margin 22.097
Pretax Margin 21.113
Net Margin 19.941
Return on Assets 5.00
Return on Equity 8.151
Return on Total Capital 5.78
Return on Invested Capital 5.98

DHR Capital Structure

Total Debt to Total Equity 36.525
Total Debt to Total Capital 26.754
Total Debt to Total Assets 23.123
Long-Term Debt to Equity 33.02
Long-Term Debt to Total Capital 24.186
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Danaher Corp. - DHR

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
22.28B 29.45B 31.47B 23.89B
Sales Growth
+24.41% +32.17% +6.85% -24.09%
Cost of Goods Sold (COGS) incl D&A
9.81B 11.50B 12.52B 9.86B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.77B 2.17B 2.22B 2.17B
Depreciation
637.00M 718.00M 738.00M 675.00M
Amortization of Intangibles
1.14B 1.45B 1.48B 1.49B
COGS Growth
+23.74% +17.25% +8.88% -21.29%
Gross Income
12.47B 17.95B 18.95B 14.03B
Gross Income Growth
+24.95% +43.90% +5.55% -25.94%
Gross Profit Margin
+55.98% +60.95% +60.21% +58.74%
2020 2021 2022 2023 5-year trend
SG&A Expense
8.16B 9.90B 10.25B 8.76B
Research & Development
1.35B 1.74B 1.75B 1.50B
Other SG&A
6.82B 8.16B 8.51B 7.25B
SGA Growth
+23.28% +21.30% +3.53% -14.60%
Other Operating Expense
- - - -
-
Unusual Expense
89.00M 400.00M 403.00M 348.00M
EBIT after Unusual Expense
4.22B 7.65B 8.29B 4.93B
Non Operating Income/Expense
545.00M 189.00M 212.00M 402.00M
Non-Operating Interest Income
71.00M 11.00M 41.00M 303.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
273.00M 241.00M 214.00M 289.00M
Interest Expense Growth
+151.38% -11.72% -11.20% +35.05%
Gross Interest Expense
273.00M 241.00M 214.00M 289.00M
Interest Capitalized
- - - -
-
Pretax Income
4.50B 7.60B 8.29B 5.04B
Pretax Income Growth
+35.99% +69.03% +9.13% -39.17%
Pretax Margin
+20.17% +25.80% +26.35% +21.11%
Income Tax
849.00M 1.25B 1.08B 823.00M
Income Tax - Current - Domestic
(249.00M) 346.00M 413.00M 756.00M
Income Tax - Current - Foreign
580.00M 1.13B 1.23B 1.27B
Income Tax - Deferred - Domestic
534.00M (206.00M) (400.00M) (866.00M)
Income Tax - Deferred - Foreign
(16.00M) (23.00M) (159.00M) (338.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
3.65B 6.35B 7.21B 4.22B
Minority Interest Expense
- - - -
-
Net Income
3.65B 6.35B 7.21B 4.22B
Net Income Growth
+49.90% +74.08% +13.58% -41.45%
Net Margin Growth
+16.36% +21.55% +22.91% +17.67%
Extraordinaries & Discontinued Operations
- - 86.00M 543.00M
-
Discontinued Operations
- - 86.00M 543.00M
-
Net Income After Extraordinaries
3.65B 6.43B 7.21B 4.76B
Preferred Dividends
136.00M 164.00M 106.00M 21.00M
Net Income Available to Common
3.51B 6.27B 7.10B 4.74B
EPS (Basic)
4.9703 8.7727 9.7959 6.4399
EPS (Basic) Growth
+42.79% +76.50% +11.66% -34.26%
Basic Shares Outstanding
706.20M 714.60M 725.10M 736.50M
EPS (Diluted)
4.8852 8.6143 9.6636 6.3827
EPS (Diluted) Growth
+42.31% +76.33% +12.18% -33.95%
Diluted Shares Outstanding
718.70M 736.80M 737.10M 743.10M
EBITDA
6.09B 10.22B 10.92B 7.45B
EBITDA Growth
+33.72% +67.87% +6.86% -31.82%
EBITDA Margin
+27.32% +34.69% +34.70% +31.16%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 290.609
Number of Ratings 28 Current Quarters Estimate 2.144
FY Report Date 12 / 2024 Current Year's Estimate 7.49
Last Quarter’s Earnings 1.71 Median PE on CY Estimate N/A
Year Ago Earnings 7.58 Next Fiscal Year Estimate 8.385
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 22 16 24 25
Mean Estimate 2.14 2.03 7.49 8.39
High Estimates 2.18 2.13 7.57 8.75
Low Estimate 2.06 1.89 7.40 8.08
Coefficient of Variance 1.22 3.70 0.43 1.97

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 18 16
OVERWEIGHT 4 3 2
HOLD 6 7 9
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Danaher Corp. - DHR

Date Name Shares Transaction Value
Jul 17, 2024 Christopher M. Bouda VP, Chief Accounting Officer 7,481 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $246.23 per share 1,842,046.63
Jul 17, 2024 Elias A. Zerhouni Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 17, 2024 Elias A. Zerhouni Director 36,780 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $246.23 per share 9,056,339.40
Jul 17, 2024 Elias A. Zerhouni Director 37,483 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $52.56 per share 1,970,106.48
Jul 17, 2024 Julie Sawyer Montgomery Executive Vice President 5,767 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $246.23 per share 1,420,008.41
Jul 17, 2024 John T. Schwieters Director 19,808 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $52.56 per share 1,041,108.48
Jul 17, 2024 John T. Schwieters Director 19,105 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $246.23 per share 4,704,224.15
Jul 17, 2024 John T. Schwieters Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 16, 2024 Rainer M. Blair President & CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 16, 2024 Rainer M. Blair President & CEO; Director 135,080 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $58.59 per share 7,914,337.20
May 16, 2024 Rainer M. Blair President & CEO; Director 121,921 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $62.85 per share 7,662,734.85
May 16, 2024 Rainer M. Blair President & CEO; Director 115,995 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $255 per share 29,578,725.00
May 16, 2024 Rainer M. Blair President & CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 14, 2024 Matthew R. McGrew EVP & Chief Financial Officer 45,338 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $62.85 per share 2,849,493.30
May 14, 2024 Matthew R. McGrew EVP & Chief Financial Officer 38,650 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $58.48 per share 2,260,252.00
May 14, 2024 Matthew R. McGrew EVP & Chief Financial Officer 32,344 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 14, 2024 Matthew R. McGrew EVP & Chief Financial Officer 29,407 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $252.94 per share 7,438,206.58
May 14, 2024 Matthew R. McGrew EVP & Chief Financial Officer 29,407 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $253.19 per share 7,445,558.33
May 14, 2024 Matthew R. McGrew EVP & Chief Financial Officer 29,407 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $253.08 per share 7,442,323.56
May 14, 2024 Matthew R. McGrew EVP & Chief Financial Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Danaher Corp. in the News